First-Trimester Levels of Pregnancy-Associated Plasma Protein A2 (PAPP-A2) in the Maternal Circulation Are Elevated in Pregnancies That Subsequently Develop Preeclampsia
Restricted accessResearch articleFirst published online June, 2014
First-Trimester Levels of Pregnancy-Associated Plasma Protein A2 (PAPP-A2) in the Maternal Circulation Are Elevated in Pregnancies That Subsequently Develop Preeclampsia
Recent studies have consistently found pregnancy-associated plasma protein A2 (PAPP-A2) to be upregulated in preeclamptic placentae at term. We tested whether first-trimester circulating PAPP-A2 levels differed between complicated and uncomplicated pregnancies. We measured maternal PAPP-A2 levels at 10 to 14 weeks of gestational age in 17 pregnancies resulting in small-for-gestational-age (SGA) infants, 6 which developed preeclampsia (PE), 1 which developed PE and resulted in an SGA infant, and 37 gestational age-matched controls. The concentration of the PAPP-A2 isoform corresponding to the full-length protein was significantly higher in pregnancies that developed PE (35 ng/mL) compared with those that did not (23 ng/mL; P < .044). In contrast, we found no difference in PAPP-A2 levels between pregnancies that did or did not result in an SGA infant. The upregulation of PAPP-A2 that has previously been observed in PE at term appears to begin early in pregnancy, well before the symptoms develop.
CrossJC. The genetics of pre-eclampsia: a feto-placental or maternal problem?Clin Genet. 2003;64(2):96–103.
2.
KinzlerWLVintzileosAM. Fetal growth restriction: a modern approach. Curr Opin Obstet Gynecol. 2008;20(2):125–131.
3.
RedmanCWSargentIL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592–1594.
4.
von DadelszenPMageeL. What matters in preeclampsia are the associated adverse outcomes: the view from Canada. Curr Opin Obstet Gynecol. 2008;20(2):110–115.
5.
GodfreyKM. The role of the placenta in fetal programming—a review. Placenta. 2002;23(suppl A):S20–S27.
6.
NayakNRGiudiceLC. Comparative biology of the IGF system in endometrium, decidua, and placenta, and clinical implications for foetal growth and implantation disorders. Placenta. 2003;24(4):281–296.
7.
Sferruzzi-PerriANOwensJAPringleKGRobertsCT. The neglected role of insulin-like growth factors in the maternal circulation regulating fetal growth. J Physiol. 2011;589(pt 1):7–20.
8.
BaxterRC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000;278(6):E967–E976.
GiudiceLCConoverCABaleL. Identification and regulation of the IGFBP-4 protease and its physiological inhibitor in human trophoblasts and endometrial stroma: evidence for paracrine regulation of IGF-II bioavailability in the placental bed during human implantation. J Clin Endocrinol Metab. 2002;87:2359–2366.
12.
BoldtHBKjaer-SorensenKOvergaardMT. The Lin12-notch repeats of pregnancy-associated plasma protein-A bind calcium and determine its proteolytic specificity. J Biol Chem. 2004;279:38525–38531.
13.
BoldtHBConoverCA. Pregnancy-associated plasma protein-A (PAPP-A): a local regulator of IGF bioavailability through cleavage of IGFBPs. Growth Horm IGF Res. 2007;17:10–18.
14.
BrambatiBMacintoshMCTeisnerB. Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype. Br J Obstet Gynaecol. 1993;100:324–326.
15.
BersingerNAOdegardRA. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand. 2004;83:37–45.
16.
DugoffLHobbinsJCMaloneFD. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol. 2004;191:1446–1451.
17.
SmithGCStenhouseEJCrossleyJAAitkenDACameronADConnorJM. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002;87:1762–1767.
18.
SpencerKYuCKCowansNJOtigbahCNicolaidesKH. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn. 2005;25:949–953.
19.
ZwahlenMGerberSBersingerNA. First trimester markers for pre-eclampsia: placental vs. non-placental protein serum levels. Gynecol Obstet Invest. 2007;63:15–21.
20.
CowansNJSpencerK. First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn. 2007;27:264–271.
21.
ZhongYTuuliMOdiboAO. First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction. Prenat Diagn. 2010;30(4):293–308.
PageNMButlinDJLomthaisongKLowryPJ. The characterization of pregnancy associated plasma protein-E and the identification of an alternative splice variant. Placenta. 2001;22(8-9):681–687.
SitrasVPaulssenRHGronaasH. Differential placental gene expression in severe preeclampsia. Placenta. 2009;30(5):424–433.
27.
NishizawaHPryor-KoishiKSuzukiM. Increased levels of pregnancy-associated plasma protein-A2 in the serum of pre-eclamptic patients. Mol Hum Reprod. 2008;14(10):595–602.
28.
WinnVDGormleyMPaquetAC. Severe preeclampsia-related changes in gene expression at the maternal-fetal interface include sialic acid-binding immunoglobulin-like lectin-6 and pappalysin-2. Endocrinology. 2009;150(1):452–462.
29.
PaivaPWhiteheadCSaglamBPalmerKTongS. Measurement of mRNA transcripts of very high placental expression in maternal blood as biomarkers of preeclampsia. J Clin Endocrinol Metab. 2011;96(11):E1807–E1815.
30.
VarkonyiTNagyBFuleT. Microarray profiling reveals that placental transcriptomes of early-onset HELLP syndrome and preeclampsia are similar. Placenta. 2011;32suppl:S21–S29.
31.
MacintireKTuoheyLYeL. PAPPA2 is increased in severe early onset pre-eclampsia and upregulated with hypoxia [published online March 14, 2013]. Reprod Fertil Dev. 2013. doi:10.1071/RD12384.
32.
DopieralaJASmithGCCharnock-JonesSD. Meta-analysis of pre-eclampsia microarray data. Reprod Sci. 2013;20(3 suppl):262A.
33.
von DadelszenPMenziesJMPayneBMageeLA; PIERS (Pre-eclampsia Integrated Estimate of RiSk) Study Group. Predicting adverse outcomes in women with severe pre-eclampsia. Semin Perinatol. 2009;33(3):152–157.
34.
WagnerPKChristiansJK. Altered placental expression of PAPPA2 does not affect birth weight in mice. Reprod Biol Endocrinol. 2010;8:90.
35.
WangJQiuQHaiderMBellMGruslinAChristiansJK. Expression of pregnancy-associated plasma protein A2 during pregnancy in human and mouse. J Endocrinol. 2009;202(3):337–345.
36.
YanXBaxterRCFirthSM. Involvement of pregnancy-associated plasma protein-A2 in insulin-like growth factor (IGF) binding protein-5 proteolysis during pregnancy: a potential mechanism for increasing IGF bioavailability. J Clin Endocrinol Metab. 2010;95(3):1412–1420.
37.
ChristiansJKGruslinA. Altered levels of insulin-like growth factor binding protein proteases in preeclampsia and intrauterine growth restriction. Prenat Diagn. 2010;30(9):815–820.
38.
WagnerPKOtomoAChristiansJK. Regulation of pregnancy-associated plasma protein A2 (PAPPA2) in a human placental trophoblast cell line (BeWo). Reprod Biol Endocrinol. 2011;9:48.
39.
KramerAHoffmanCLynchAWinnVD. Maternal serum PAPP-A2 levels are elevated in early onset preeclampsia at time of diagnosis and in early gestation. Reprod Sci. 2012;19(3 suppl):87A.
40.
PoonLCStratievaVPirasSPiriSNicolaidesKH. Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks. Prenat Diagn. 2010;30(3):216–223.
41.
WhiteheadCLWalkerSPYeL. Placental specific mRNA in the maternal circulation are globally dysregulated in pregnancies complicated by fetal growth restriction. J Clin Endocrinol Metab. 2013;98(3):E429–E436.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
